Drug Profile


Alternative Names: Bupropion SR/zonisamide IR; Bupropion SR/zonisamide SR; Empatic™; Excalia™; Zonisamide IR/bupropion SR; Zonisamide SR/bupropion SR; Zonisamide/bupropion

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orexigen Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Isoxazoles; Obesity therapies; Propiophenones; Sulfonamides
  • Mechanism of Action Adrenergic uptake inhibitors; Antioxidants; Calcium channel antagonists; Dopamine release stimulants; Dopamine uptake inhibitors; Neuron inhibitors; Serotonin release stimulants; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 20 Mar 2013 Bupropion/Zonisamide is available for licensing as of 20 Mar 2013. www.orexigen.com
  • 30 Sep 2009 Efficacy and adverse events data from a phase IIb trial in obesity released by Orexigen Therapeutics
  • 09 Oct 2008 Data from two post-hoc analyses from a phase IIb trial in Obesity presented at the 2008 Obesity Society Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top